Xenetic Biosciences XBIO
NASDAQ XBIO
$2.22 -0.10 (-4.31%)
As of: Oct 1, 2026 · 11:11 AM EDT

Xenetic Biosciences (XBIO) Current Deferred Revenue (2016 - 2018)

Updated

Xenetic Biosciences (XBIO) recorded Current Deferred Revenue of $6,703 in Q3 2018, down 68.2% from $21,071 a year earlier and down 41.2% from the prior quarter.

Analysis

Xenetic Biosciences (XBIO) Current Deferred Revenue (2016 - 2018) Analysis & Trends

At the end of FY2017, Xenetic Biosciences reported Current Deferred Revenue of $21,234, up 5.1% from FY2016.

  • Across earlier years, Current Deferred Revenue came in at $20,205 in FY2016.
  • Per Business Quant, the preceding three quarters came in at $11,394 (Q2 2018), $16,371 (Q1 2018) and $21,234 (Q4 2017).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Xenetic Biosciences 5.44 Mn -20.39 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2018 6,703.00
Jun 30, 2018 11,394.00
Mar 31, 2018 16,371.00
Dec 31, 2017 21,234.00
Sep 30, 2017 21,071.00
Jun 30, 2017 67,495.00
Dec 31, 2016 20,205.00
API Access

Xenetic Biosciences Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=XBIO&period=max&api_key=YOUR_API_KEY